These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 25390539)

  • 21. Cystoid macular edema associated with juvenile idiopathic arthritis resolved by a dexamethasone intravitreal implant.
    Totan Y; Güler E; Guragaç FB; Dervisogullari MS; Tenlik A; Hepsen IF
    J Pediatr Ophthalmol Strabismus; 2014 May; 51 Online():e25-8. PubMed ID: 24811080
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Intravitreal triamcinolone acetonide for treatment of intraocular oedematous and neovascular diseases.
    Jonas JB
    Acta Ophthalmol Scand; 2005 Dec; 83(6):645-63. PubMed ID: 16396641
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Corneal graft failure due to migration of Ozurdex™ implant into the anterior chamber.
    Madi HA; Morgan SJ; Ghosh S
    Am J Ophthalmol Case Rep; 2017 Dec; 8():25-27. PubMed ID: 29260111
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Resolution of refractory macular edema because of branch retinal vein occlusion after ozurdex implantation.
    Kay CN; Elkins KA; Folk JC
    Retin Cases Brief Rep; 2012; 6(1):72-5. PubMed ID: 25390716
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of intravitreal injection of bevacizumab and triamcinolone acetonide in the treatment of uveitic macular edema.
    Rahimi M; Shahrzad SS; Banifatemi M
    Iran J Immunol; 2012 Jun; 9(2):136-44. PubMed ID: 22735801
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Complications of dexamethasone implants: risk factors, prevention, and clinical management.
    Celik N; Khoramnia R; Auffarth GU; Sel S; Mayer CS
    Int J Ophthalmol; 2020; 13(10):1612-1620. PubMed ID: 33078113
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Management of anterior chamber dislocation of dexamethasone implant.
    Kishore SA; Schaal S
    Ocul Immunol Inflamm; 2013; 21(1):90-1. PubMed ID: 23323589
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Intravitreal dexamethasone implant for refractory macular edema secondary to vitrectomy for macular pucker.
    Furino C; Boscia F; Recchimurzo N; Sborgia C; Alessio G
    Retina; 2014 Aug; 34(8):1612-6. PubMed ID: 24752008
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Migration of a Dexamethasone Intravitreal Implant to the Anterior Chamber in a Patient with a Intra-Scleral Haptic Fixated Intraocular Lens.
    Jamshidi F; Shah VA; Riaz KM
    Int Med Case Rep J; 2021; 14():633-635. PubMed ID: 34566437
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of intravitreal bevacizumab upload followed by a dexamethasone implant versus dexamethasone implant monotherapy for retinal vein occlusion with macular edema.
    Mayer WJ; Remy M; Wolf A; Kook D; Kampik A; Ulbig M; Reznicek L; Haritoglou C
    Ophthalmologica; 2012; 228(2):110-6. PubMed ID: 22739239
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prospective study of intravitreal triamcinolone acetonide versus bevacizumab for macular edema secondary to central retinal vein occlusion.
    Ding X; Li J; Hu X; Yu S; Pan J; Tang S
    Retina; 2011 May; 31(5):838-45. PubMed ID: 21293319
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Intravitreal VEGF levels in uveitis patients and treatment of uveitic macular oedema with intravitreal bevacizumab.
    Weiss K; Steinbrugger I; Weger M; Ardjomand N; Maier R; Wegscheider BJ; Wedrich A; El-Shabrawi Y
    Eye (Lond); 2009 Sep; 23(9):1812-8. PubMed ID: 19169227
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacokinetics of a sustained-release dexamethasone intravitreal implant in vitrectomized and nonvitrectomized eyes.
    Chang-Lin JE; Burke JA; Peng Q; Lin T; Orilla WC; Ghosn CR; Zhang KM; Kuppermann BD; Robinson MR; Whitcup SM; Welty DF
    Invest Ophthalmol Vis Sci; 2011 Jun; 52(7):4605-9. PubMed ID: 21421864
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Outcome of intravitreal triamcinolone acetonide in postoperative cystoid macular oedema.
    Konstantopoulos A; Williams CP; Luff AJ
    Eye (Lond); 2008 Feb; 22(2):219-22. PubMed ID: 17016463
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of intravitreal versus posterior sub-Tenon's capsule injection of triamcinolone acetonide for diffuse diabetic macular edema.
    Cardillo JA; Melo LA; Costa RA; Skaf M; Belfort R; Souza-Filho AA; Farah ME; Kuppermann BD
    Ophthalmology; 2005 Sep; 112(9):1557-63. PubMed ID: 16019075
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Intravitreal triamcinolone acetonide for cystoid macular edema secondary to central serous chorioretinopathy.
    Patron ME; Vuong LN; Duker JS
    Retin Cases Brief Rep; 2009; 3(3):319-22. PubMed ID: 25389597
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Safety and efficacy of intraoperative intravitreal injection of triamcinolone acetonide injection after phacoemulsification in cases of uveitic cataract.
    Dada T; Dhawan M; Garg S; Nair S; Mandal S
    J Cataract Refract Surg; 2007 Sep; 33(9):1613-8. PubMed ID: 17720079
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Intravitreal triamcinolone.
    Tao Y; Jonas JB
    Ophthalmologica; 2011; 225(1):1-20. PubMed ID: 20693817
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Treatment of anti-vascular endothelial growth factor-resistant diabetic macular edema with dexamethasone intravitreal implant.
    Lazic R; Lukic M; Boras I; Draca N; Vlasic M; Gabric N; Tomic Z
    Retina; 2014 Apr; 34(4):719-24. PubMed ID: 23975006
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Intravitreal triamcinolone acetonide for treatment of intraocular proliferative, exudative, and neovascular diseases.
    Jonas JB; Kreissig I; Degenring R
    Prog Retin Eye Res; 2005 Sep; 24(5):587-611. PubMed ID: 16005407
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.